International Journal of Cancer Management

Published by: Kowsar

Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues

S. Saeed Mohammadi 1 , 2 , Farideh Hosseinzadeh 1 , 2 and Foroogh Nejatollahi 1 , 2 , *
Authors Information
1 Recombinant Antibody Laboratory, Department of Immunology, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: January 2017, 10 (1); e6666
  • Published Online: January 24, 2017
  • Article Type: Research Article
  • Received: May 3, 2016
  • Revised: June 8, 2016
  • Accepted: January 3, 2017
  • DOI: 10.17795/ijcp-6666

To Cite: Mohammadi S S, Hosseinzadeh F, Nejatollahi F. Production of Specific Anti-EGFR Single Chain Antibodies: A Promising Strategy in the Immunotherapy of EGFR Expressing Tumor Tissues, Int J Cancer Manag. 2017 ; 10(1):e6666. doi: 10.17795/ijcp-6666.

Abstract
Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003; 284(1): 31-53[PubMed]
  • 2. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001; 8(1): 11-31[PubMed]
  • 3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2): 127-37[DOI][PubMed]
  • 4. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control. 2007; 14(3): 295-304[PubMed]
  • 5. Zhu X, Zhang F, Zhang W, He J, Zhao Y, Chen X. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol. 2013; 108(6): 387-97[DOI][PubMed]
  • 6. Merseburger AS, Hennenlotter J, Simon P, Kruck S, Koch E, Horstmann M, et al. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res. 2005; 25(3B): 1901-7[PubMed]
  • 7. Bichev SN, Marinova DM, Slavova YG, Savov AS. Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients. Cell Oncol (Dordr). 2015; 38(2): 145-53[DOI][PubMed]
  • 8. Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 2012; 36(5): 490-6[DOI][PubMed]
  • 9. Cervantes A. Exploring better strategies for EGFR antibodies in colon cancer. Lancet Oncol. 2014; 15(6): 549-50[DOI][PubMed]
  • 10. Sartor CI. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Semin Oncol. 2000; 27(6 Suppl 11): 15-20[PubMed]
  • 11. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther. 1999; 82(2-3): 207-18[PubMed]
  • 12. Ono Y, Toyota Y, Toyoshima A, Kuramoto S, Katzumata A, Kawauchi M, et al. [Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation]. No Shinkei Geka. 2011; 39(6): 569-74[PubMed]
  • 13. Bontognali S, Pless M, Brutsche MH, Fischer C, Rochlitz C, Buess M. Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie. 2013; 36(4): 161-6[DOI][PubMed]
  • 14. Manegold C. Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. Adv Med Sci. 2014; 59(2): 308-13[DOI][PubMed]
  • 15. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol. 2000; 11 Suppl 3: 187-90[PubMed]
  • 16. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 2010; 10(1): 80-95[PubMed]
  • 17. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors. 2008; 26(5): 263-74[DOI][PubMed]
  • 18. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012; 2012: 980250[DOI][PubMed]
  • 19. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52(12): 3402-8[PubMed]
  • 20. Nejatollahi F, Jaberipour M, Asgharpour M. Triple blockade of HER2 by a cocktail of anti-HER2 scFv antibodies induces high antiproliferative effects in breast cancer cells. Tumour Biol. 2014; 35(8): 7887-95[DOI][PubMed]
  • 21. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61(12): 4750-5[PubMed]
  • 22. Mohammadi M, Nejatollahi F. 3D structural modeling of neutralizing scFv against glycoprotein-D of HSV-1 and evaluation of antigen-antibody interactions by bioinformatic methods. Int J Pharm Bio Sci. 2014; 5(4): 835-47
  • 23. Nejatollahi F, Ranjbar R, Younesi V, Asgharpour M. Deregulation of HER2 downstream signaling in breast cancer cells by a cocktail of anti-HER2 scFvs. Oncol Res. 2013; 20(8): 333-40[DOI][PubMed]
  • 24. Nejatollahi F, Hodgetts SJ, Vallely PJ, Burnie JP. Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH. FEMS Immunol Med Microbiol. 2002; 34(3): 237-44[PubMed]
  • 25. Nejatollahi F, Malek-Hosseini Z, Mehrabani D. Development of single chain antibodies to P185 tumor antigen. Iran Red Crescent Med J. 2008; 2008(4): 298-302
  • 26. Baselga J. The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer. 2001; 37 Suppl 4-22[PubMed]
  • 27. Messersmith WA, Hidalgo M. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one? Clin Cancer Res. 2007; 13(16): 4664-6[DOI][PubMed]
  • 28. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005; 23(9): 1126-36[DOI][PubMed]
  • 29. Malpiedi LP, Díaz CA, Nerli BB, Pessoa A. Single-chain antibody fragments: Purification methodologies. Proc Biochem. 2013; 48(8): 1242-51[DOI]
  • 30. Farajnia S, Ahmadzadeh V, Tanomand A, Veisi K, Khosroshahi SA, Rahbarnia L. Development trends for generation of single-chain antibody fragments. Immunopharmacol Immunotoxicol. 2014; 36(5): 297-308[DOI][PubMed]
  • 31. Ottiger M, Thiel MA, Feige U, Lichtlen P, Urech DM. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci. 2009; 50(2): 779-86[DOI][PubMed]
  • 32. Karwa R, Wargo KA. Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009; 43(11): 1818-23[DOI][PubMed]
  • 33. von Minckwitz G, Harder S, Hovelmann S, Jager E, Al-Batran SE, Loibl S, et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res. 2005; 7(5)-26[DOI][PubMed]
  • 34. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 2002; 110(6): 763-73[PubMed]
  • 35. Chao G, Olsen M, Wolf-Yadlin A, Wittrup K, Lauffenburger D. Epidermal growth factor receptor polypeptides and antibodies. 2007;
  • 36. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3): 183-232[PubMed]
  • 37. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PJ. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002; 29(1 Suppl 4): 3-14[PubMed]
  • 38. Nejatollahi F, Abdi S, Asgharpour M. Antiproliferative and apoptotic effects of a specific antiprostate stem cell single chain antibody on human prostate cancer cells. J Oncol. 2013; 2013: 839831[DOI][PubMed]
  • 39. Younesi V, Nejatollahi F. Induction of anti-proliferative and apoptotic effects by anti-IL-25 receptor single chain antibodies in breast cancer cells. Int Immunopharmacol. 2014; 23(2): 624-32[DOI][PubMed]
  • 40. Luo Y, Pang H, Li S, Cao H, Peng Z, Fan C, et al. Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther. 2009; 8(14): 1369-77[PubMed]
  • 41. Thathaisong U, Maneewatch S, Kulkeaw K, Thueng-In K, Poungpair O, Srimanote P, et al. Human monoclonal single chain antibodies (HuScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac J Allergy Immunol. 2008; 26(1): 23-35[PubMed]
  • 42. Ranjbar R, Nejatollahi F, Ahmadi ASN, Hafezi H, Safaie A. Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) in Patients With Serous Ovarian Carcinoma and Their Clinical Significance. Iran J Cancer Prev. 2015; 8(4)[DOI]
  • 43. Nejatollahi F, Asgharpour M, Jaberipour M. Down-regulation of vascular endothelial growth factor expression by anti-Her2/neu single chain antibodies. Med Oncol. 2012; 29(1): 378-83[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments